{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:24:54Z","timestamp":1761744294432},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T00:00:00Z","timestamp":1460332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12020-016-0940-7","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T10:36:27Z","timestamp":1460630187000},"page":"28-34","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Non-functioning pituitary adenomas: growth and aggressiveness"],"prefix":"10.1007","volume":"53","author":[{"given":"Kristin Astrid","family":"\u00d8ystese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan Arild","family":"Evang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Bollerslev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"issue":"3","key":"940_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-013-1354-5","volume":"117","author":"ED Aflorei","year":"2014","unstructured":"E.D. Aflorei, M. Korbonits, Epidemiology and etiopathogenesis of pituitary adenomas. J. Neurooncol. 117(3), 379\u2013394 (2014). doi: 10.1007\/s11060-013-1354-5","journal-title":"J. Neurooncol."},{"key":"940_CR2","doi-asserted-by":"publisher","first-page":"756069","DOI":"10.1155\/2015\/756069","volume":"2015","author":"G Vargas","year":"2015","unstructured":"G. Vargas, B. Gonzalez, C. Ramirez, A. Ferreira, E. Espinosa, V. Mendoza, G. Guinto, B. Lopez-Felix, E. Zepeda, M. Mercado, Clinical characteristics and treatment outcome of 485 patients with nonfunctioning pituitary macroadenomas. Int. J. Endocrinol. 2015, 756069 (2015). doi: 10.1155\/2015\/756069","journal-title":"Int. J. Endocrinol."},{"issue":"4","key":"940_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.beem.2012.01.002","volume":"26","author":"O Cooper","year":"2012","unstructured":"O. Cooper, S. Melmed, Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best practice & research. Clinical. Endocrinol. Metab 26(4), 447\u2013460 (2012). doi: 10.1016\/j.beem.2012.01.002","journal-title":"Endocrinol. Metab"},{"issue":"4","key":"940_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000430815","volume":"102","author":"G Carosi","year":"2015","unstructured":"G. Carosi, E. Malchiodi, E. Ferrante, E. Sala, E. Verrua, E. Profka, C. Giavoli, M. Filopanti, P. Beck-Peccoz, A. Spada, G. Mantovani, Hypothalamic-pituitary axis in non-functioning pituitary adenomas: focus on the prevalence of isolated central hypoadrenalism. Neuroendocrinology 102(4), 267\u2013273 (2015). doi: 10.1159\/000430815","journal-title":"Neuroendocrinology"},{"issue":"5777","key":"940_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1126\/science.1126100","volume":"312","author":"O Vierimaa","year":"2006","unstructured":"O. Vierimaa, M. Georgitsi, R. Lehtonen, P. Vahteristo, A. Kokko, A. Raitila, K. Tuppurainen, T.M. Ebeling, P.I. Salmela, R. Paschke, S. Gundogdu, E. De Menis, M.J. Makinen, V. Launonen, A. Karhu, L.A. Aaltonen, Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777), 1228\u20131230 (2006). doi: 10.1126\/science.1126100","journal-title":"Science"},{"issue":"6","key":"940_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11102-015-0652-7","volume":"18","author":"C Esteves","year":"2015","unstructured":"C. Esteves, C. Neves, L. Augusto, J. Menezes, J. Pereira, I. Bernardes, J. Fonseca, D. Carvalho, Pituitary incidentalomas: analysis of a neuroradiological cohort. Pituitary 18(6), 777\u2013781 (2015). doi: 10.1007\/s11102-015-0652-7","journal-title":"Pituitary"},{"issue":"5","key":"940_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/eje-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir, G. Sigurdsson, A.V. Thorsson, P.V. Carroll, M. Korbonits, R. Benediktsson, The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur. J. Endocrinol. 173(5), 655\u2013664 (2015). doi: 10.1530\/eje-15-0189","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"940_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/eje-14-0144","volume":"171","author":"A Tjornstrand","year":"2014","unstructured":"A. Tjornstrand, K. Gunnarsson, M. Evert, E. Holmberg, O. Ragnarsson, T. Rosen, Filipsson Nystrom, H.: the incidence rate of pituitary adenomas in western Sweden for the period 2001\u20132011. Eur. J. Endocrinol. 171(4), 519\u2013526 (2014). doi: 10.1530\/eje-14-0144","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"940_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72(3), 377\u2013382 (2010). doi: 10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"12","key":"940_CR10","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91(12), 4769\u20134775 (2006). doi: 10.1210\/jc.2006-1668","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"940_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","volume":"10","author":"A Ieva Di","year":"2014","unstructured":"A. Di Ieva, F. Rotondo, L.V. Syro, M.D. Cusimano, K. Kovacs, Aggressive pituitary adenomas\u2013diagnosis and emerging treatments. Nat. Rev. Endocrinol. 10(7), 423\u2013435 (2014). doi: 10.1038\/nrendo.2014.64","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"940_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ecl.2014.11.001","volume":"44","author":"SE Mayson","year":"2015","unstructured":"S.E. Mayson, P.J. Snyder, Silent pituitary adenomas. Endocrinol. Metab. Clin. North Am. 44(1), 79\u201387 (2015). doi: 10.1016\/j.ecl.2014.11.001","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"4","key":"940_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","volume":"26","author":"H Nishioka","year":"2015","unstructured":"H. Nishioka, N. Inoshita, O. Mete, S.L. Asa, K. Hayashi, A. Takeshita, N. Fukuhara, M. Yamaguchi-Okada, Y. Takeuchi, S. Yamada, The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr. Pathol. 26(4), 349\u2013355 (2015). doi: 10.1007\/s12022-015-9398-z","journal-title":"Endocr. Pathol."},{"key":"940_CR14","unstructured":"R. DeLellis, P. Heitz, World Health Organization Classification of Tumours: Tumours of Endocrine Organs. IARC PRess, Lyon (2004)"},{"issue":"5","key":"940_CR15","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1210\/jc.2011-3163","volume":"97","author":"C Ramirez","year":"2012","unstructured":"C. Ramirez, S. Cheng, G. Vargas, S.L. Asa, S. Ezzat, B. Gonzalez, L. Cabrera, G. Guinto, M. Mercado, Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J. Clin. Endocrinol. Metab. 97(5), 1745\u20131751 (2012). doi: 10.1210\/jc.2011-3163","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"940_CR16","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.humpath.2011.12.003","volume":"43","author":"A Righi","year":"2012","unstructured":"A. Righi, P. Agati, A. Sisto, G. Frank, M. Faustini-Fustini, R. Agati, D. Mazzatenta, A. Farnedi, F. Menetti, G. Marucci, M.P. Foschini, A classification tree approach for pituitary adenomas. Hum. Pathol. 43(10), 1627\u20131637 (2012). doi: 10.1016\/j.humpath.2011.12.003","journal-title":"Hum. Pathol."},{"issue":"1","key":"940_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","volume":"126","author":"J Trouillas","year":"2013","unstructured":"J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.F. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornelius, H. Dufour, E. Jouanneau, P. Francois, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C.A. Maurage, D. Figarella-Branger, G. Raverot, A. Barlier, M. Bernier, F. Bonnet, F. Borson-Chazot, G. Brassier, S. Caulet-Maugendre, O. Chabre, P. Chanson, J.F. Cottier, B. Delemer, E. Delgrange, L. Di Tommaso, S. Eimer, S. Gaillard, M. Jan, J.J. Girard, V. Lapras, H. Loiseau, J.G. Passagia, M. Patey, A. Penfornis, J.Y. Poirier, G. Perrin, A. Tabarin, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8\u00a0years post-operative follow-up. Acta Neuropathol. 126(1), 123\u2013135 (2013). doi: 10.1007\/s00401-013-1084-y","journal-title":"Acta Neuropathol."},{"issue":"3","key":"940_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/00313020701329914","volume":"39","author":"M Guarino","year":"2007","unstructured":"M. Guarino, B. Rubino, G. Ballabio, The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39(3), 305\u2013318 (2007). doi: 10.1080\/00313020701329914","journal-title":"Pathology"},{"issue":"5","key":"940_CR19","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2009-2197","volume":"95","author":"SL Fougner","year":"2010","unstructured":"S.L. Fougner, T. Lekva, O.C. Borota, J.K. Hald, J. Bollerslev, J.P. Berg, The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95(5), 2334\u20132342 (2010). doi: 10.1210\/jc.2009-2197","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"940_CR20","doi-asserted-by":"publisher","first-page":"E1506","DOI":"10.1210\/jc.2012-1760","volume":"97","author":"T Lekva","year":"2012","unstructured":"T. Lekva, J.P. Berg, S.L. Fougner, O.K. Olstad, T. Ueland, J. Bollerslev, Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J. Clin. Endocrinol. Metab. 97(8), E1506\u2013E1514 (2012). doi: 10.1210\/jc.2012-1760","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"940_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2265.2011.04109.x","volume":"75","author":"JA Evang","year":"2011","unstructured":"J.A. Evang, J.P. Berg, O. Casar-Borota, T. Lekva, M.K. Kringen, J. Ramm-Pettersen, J. Bollerslev, Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin. Endocrinol. (Oxf) 75(6), 811\u2013818 (2011). doi: 10.1111\/j.1365-2265.2011.04109.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"3","key":"940_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00701-013-1959-7","volume":"156","author":"H Halvorsen","year":"2014","unstructured":"H. Halvorsen, J. Ramm-Pettersen, R. Josefsen, P. Ronning, S. Reinlie, T. Meling, J. Berg-Johnsen, J. Bollerslev, E. Helseth, Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochir. (Wien) 156(3), 441\u2013449 (2014). doi: 10.1007\/s00701-013-1959-7","journal-title":"Acta Neurochir. (Wien)"},{"issue":"1","key":"940_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00701-006-1044-6","volume":"149","author":"J Honegger","year":"2007","unstructured":"J. Honegger, U. Ernemann, T. Psaras, B. Will, Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Acta Neurochir. 149(1), 21\u201329 (2007). doi: 10.1007\/s00701-006-1044-6","journal-title":"Acta Neurochir."},{"issue":"5","key":"940_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1530\/eje-11-0566","volume":"165","author":"R Reddy","year":"2011","unstructured":"R. Reddy, S. Cudlip, J.V. Byrne, N. Karavitaki, J.A. Wass, Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur. J. Endocrinol. 165(5), 739\u2013744 (2011). doi: 10.1530\/eje-11-0566","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"940_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/bf03350330","volume":"21","author":"A Colao","year":"1998","unstructured":"A. Colao, G. Cerbone, P. Cappabianca, D. Ferone, A. Alfieri, F. Di Salle, A. Faggiano, B. Merola, E. de Divitiis, G. Lombardi, Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. J. Endocrinol. Invest. 21(5), 284\u2013290 (1998). doi: 10.1007\/bf03350330","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"940_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11060-014-1501-7","volume":"119","author":"D Ding","year":"2014","unstructured":"D. Ding, C.P. Yen, R.M. Starke, C.C. Lee, J.P. Sheehan, Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy. J. Neurooncol. 119(3), 513\u2013529 (2014). doi: 10.1007\/s11060-014-1501-7","journal-title":"J. Neurooncol."},{"issue":"1","key":"940_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ecl.2014.10.009","volume":"44","author":"G Ntali","year":"2015","unstructured":"G. Ntali, N. Karavitaki, Efficacy and complications of pituitary irradiation. Endocrinol. Metab. Clin. North Am. 44(1), 117\u2013126 (2015). doi: 10.1016\/j.ecl.2014.10.009","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"3","key":"940_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jc.2014-3697","volume":"100","author":"NC Varsseveld van","year":"2015","unstructured":"N.C. van Varsseveld, C.C. van Bunderen, D.H. Ubachs, A.A. Franken, H.P. Koppeschaar, A.J. van der Lely, M.L. Drent, Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the dutch national registry of growth hormone treatment in adults. J. Clin. Endocrinol. Metab. 100(3), 1104\u20131112 (2015). doi: 10.1210\/jc.2014-3697","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"940_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-013-1262-8","volume":"117","author":"D Ding","year":"2014","unstructured":"D. Ding, R.M. Starke, J.P. Sheehan, Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. J. Neurooncol. 117(3), 445\u2013457 (2014). doi: 10.1007\/s11060-013-1262-8","journal-title":"J. Neurooncol."},{"issue":"2","key":"940_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","volume":"101","author":"E Chatzellis","year":"2015","unstructured":"E. Chatzellis, K.I. Alexandraki, I.I. Androulakis, G. Kaltsas, Aggressive pituitary tumors. Neuroendocrinology 101(2), 87\u2013104 (2015). doi: 10.1159\/000371806","journal-title":"Neuroendocrinology"},{"issue":"7","key":"940_CR31","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3109\/0284186x.2013.818255","volume":"52","author":"SE Combs","year":"2013","unstructured":"S.E. Combs, K. Kessel, D. Habermehl, T. Haberer, O. Jakel, J. Debus, Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol. 52(7), 1504\u20131509 (2013). doi: 10.3109\/0284186x.2013.818255","journal-title":"Acta Oncol."},{"issue":"3","key":"940_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ijrobp.2014.06.068","volume":"90","author":"DA Wattson","year":"2014","unstructured":"D.A. Wattson, S.K. Tanguturi, D.Y. Spiegel, A. Niemierko, B.M. Biller, L.B. Nachtigall, M.R. Bussiere, B. Swearingen, P.H. Chapman, J.S. Loeffler, H.A. Shih, Outcomes of proton therapy for patients with functional pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 90(3), 532\u2013539 (2014). doi: 10.1016\/j.ijrobp.2014.06.068","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"940_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/cen.12684","volume":"82","author":"Vieira Neto","year":"2015","unstructured":"Vieira Neto, L. Wildemberg, L.E. Moraes, A.B. Colli, L.M. Kasuki, N.V. Marques, E.L. Gasparetto, M. Takiya, C.M. Gadelha, Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin. Endocrinol. (Oxf) 82(5), 739\u2013746 (2015). doi: 10.1111\/cen.12684","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"940_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12020-015-0685-8","volume":"50","author":"Y Greenman","year":"2015","unstructured":"Y. Greenman, N. Stern, Optimal management of non-functioning pituitary adenomas. Endocrine 50(1), 51\u201355 (2015). doi: 10.1007\/s12020-015-0685-8","journal-title":"Endocrine"},{"key":"940_CR35","unstructured":"St. Olavs Hospital; Norwegian University of Science Technology: Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs)\u2014a randomized controlled trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US)"},{"issue":"3","key":"940_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","volume":"68","author":"SL Fougner","year":"2008","unstructured":"S.L. Fougner, O.C. Borota, J.P. Berg, J.K. Hald, J. Ramm-Pettersen, J. Bollerslev, The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. (Oxf) 68(3), 458\u2013465 (2008). doi: 10.1111\/j.1365-2265.2007.03065.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"5","key":"940_CR37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707\u2013716 (2002)","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"940_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/eje-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"D. Iacovazzo, E. Carlsen, F. Lugli, S. Chiloiro, S. Piacentini, A. Bianchi, A. Giampietro, M. Mormando, A.J. Clear, F. Doglietto, C. Anile, G. Maira, L. Lauriola, G. Rindi, F. Roncaroli, A. Pontecorvi, M. Korbonits, L. De Marinis, Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174(2), 241\u2013250 (2016). doi: 10.1530\/eje-15-0832","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"940_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2010.08.011","volume":"331","author":"H Nishioka","year":"2011","unstructured":"H. Nishioka, K. Tamura, H. Iida, M. Kutsukake, A. Endo, Y. Ikeda, J. Haraoka, Co-expression of somatostatin receptor subtypes and estrogen receptor-alpha mRNAs by non-functioning pituitary adenomas in young patients. Mol. Cell. Endocrinol. 331(1), 73\u201378 (2011). doi: 10.1016\/j.mce.2010.08.011","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"940_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1530\/eje.1.02313","volume":"156","author":"GF Taboada","year":"2007","unstructured":"G.F. Taboada, R.M. Luque, W. Bastos, R.F. Guimaraes, J.B. Marcondes, L.M. Chimelli, R. Fontes, P.J. Mata, P.N. Filho, D.P. Carvalho, R.D. Kineman, M.R. Gadelha, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur. J. Endocrinol. 156(1), 65\u201374 (2007). doi: 10.1530\/eje.1.02313","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"940_CR41","doi-asserted-by":"publisher","first-page":"e77406","DOI":"10.1371\/journal.pone.0077406","volume":"8","author":"Vieria Neto","year":"2013","unstructured":"Vieria Neto, L., Wildemberg, L.E., Colli, L.M., Kasuki, L., Marques, N.V., Moraes, A.B., Gasparetto, E.L., Takiya, C.M., Castro, M., Gadelha, M.R.: zAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas. PLoS ONE 8(10), e77406 (2013). doi: 10.1371\/journal.pone.0077406","journal-title":"PLoS ONE"},{"issue":"7","key":"940_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/bf03348901","volume":"16","author":"M Gasperi","year":"1993","unstructured":"M. Gasperi, L. Petrini, R. Pilosu, M. Nardi, A. Marcello, F. Mastio, L. Bartalena, E. Martino, Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J. Endocrinol. Invest. 16(7), 541\u2013543 (1993). doi: 10.1007\/bf03348901","journal-title":"J. Endocrinol. Invest."},{"issue":"4","key":"940_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","volume":"15","author":"A Fusco","year":"2012","unstructured":"A. Fusco, A. Giampietro, A. Bianchi, V. Cimino, F. Lugli, S. Piacentini, M. Lorusso, A. Tofani, G. Perotti, L. Lauriola, C. Anile, G. Maira, A. Pontecorvi, L. De Marinis, Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15(4), 571\u2013578 (2012). doi: 10.1007\/s11102-011-0370-8","journal-title":"Pituitary"},{"issue":"1","key":"940_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1530\/erc-14-0472","volume":"22","author":"M Lee","year":"2015","unstructured":"M. Lee, A. Lupp, N. Mendoza, N. Martin, R. Beschorner, J. Honegger, J. Schlegel, T. Shively, E. Pulz, S. Schulz, F. Roncaroli, N.S. Pellegata, SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr. Relat. Cancer 22(1), 111\u2013119 (2015). doi: 10.1530\/erc-14-0472","journal-title":"Endocr. Relat. Cancer"},{"key":"940_CR45","unstructured":"Novartis, P., Novartis: Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. In. Bethesda (MD): National Library of Medicine (US) (2016)"},{"issue":"4","key":"940_CR46","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"D. Bengtsson, H.D. Schroder, M. Andersen, D. Maiter, K. Berinder, Feldt Rasmussen, U., Rasmussen, A.K., Johannsson, G., Hoybye, C., van der Lely, A.J., Petersson, M., Ragnarsson, O., Burman, P.: long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J. Clin. Endocrinol. Metabo. 100(4), 1689\u20131698 (2015). doi: 10.1210\/jc.2014-4350","journal-title":"J. Clin. Endocrinol. Metabo."},{"issue":"6","key":"940_CR47","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","volume":"76","author":"G Raverot","year":"2012","unstructured":"G. Raverot, F. Castinetti, E. Jouanneau, I. Morange, D. Figarella-Branger, H. Dufour, J. Trouillas, T. Brue, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. (Oxf) 76(6), 769\u2013775 (2012). doi: 10.1111\/j.1365-2265.2012.04381.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"940_CR48","unstructured":"G. Raverot, P. Burman, A. McCormack, S. Petersenn, V. Popovic-Brkic, J. Trouillas, ESE Survey on Aggressive Pituitary Tumors. http:\/\/www.ese-hormones.org\/professional\/"},{"issue":"4","key":"940_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000339823","volume":"96","author":"Y Chen","year":"2012","unstructured":"Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4), 333\u2013342 (2012). doi: 10.1159\/000339823","journal-title":"Neuroendocrinology"},{"issue":"4","key":"940_CR50","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1210\/jc.2013-3054","volume":"99","author":"E Monsalves","year":"2014","unstructured":"E. Monsalves, S. Larjani, B. Loyola Godoy, K. Juraschka, F. Carvalho, W. Kucharczyk, A. Kulkarni, O. Mete, F. Gentili, S. Ezzat, G. Zadeh, Growth patterns of pituitary adenomas and histopathological correlates. J. Clin. Endocrinol. Metab. 99(4), 1330\u20131338 (2014). doi: 10.1210\/jc.2013-3054","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"940_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ando.2015.04.003","volume":"76","author":"C Cortet-Rudelli","year":"2015","unstructured":"C. Cortet-Rudelli, J.F. Bonneville, F. Borson-Chazot, L. Clavier, B. Coche Dequeant, R. Desailloud, D. Maiter, V. Rohmer, J.L. Sadoul, E. Sonnet, P. Toussaint, P. Chanson, Post-surgical management of non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76(3), 228\u2013238 (2015). doi: 10.1016\/j.ando.2015.04.003","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"940_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1055\/s-0035-1549307","volume":"76","author":"HM Kistka","year":"2015","unstructured":"H.M. Kistka, R.A. Kasl, A. Nayeri, A.L. Utz, K.D. Weaver, L.B. Chambless, Imaging of resected nonfunctioning pituitary adenomas: the cost of surveillance. J. Neurol. Surg. 76(5), 344\u2013350 (2015). doi: 10.1055\/s-0035-1549307","journal-title":"J. Neurol. Surg."},{"issue":"4","key":"940_CR53","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1210\/jc.2010-1048","volume":"96","author":"PU Freda","year":"2011","unstructured":"P.U. Freda, A.M. Beckers, L. Katznelson, M.E. Molitch, V.M. Montori, K.D. Post, M.L. Vance, Pituitary incidentaloma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(4), 894\u2013904 (2011). doi: 10.1210\/jc.2010-1048","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"940_CR54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/eje.0.1460179","volume":"146","author":"G Soto-Ares","year":"2002","unstructured":"G. Soto-Ares, C. Cortet-Rudelli, R. Assaker, A. Boulinguez, C. Dubest, D. Dewailly, J.P. Pruvo, MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur. J. Endocrinol. 146(2), 179\u2013186 (2002)","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"940_CR55","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2265.2009.03583.x","volume":"71","author":"EP O\u2019Sullivan","year":"2009","unstructured":"E.P. O\u2019Sullivan, C. Woods, N. Glynn, L.A. Behan, R. Crowley, P. O\u2019Kelly, D. Smith, C.J. Thompson, A. Agha, The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin. Endocrinol. (Oxf) 71(5), 709\u2013714 (2009). doi: 10.1111\/j.1365-2265.2009.03583.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"940_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12879","author":"N Lenders","year":"2015","unstructured":"N. Lenders, S. Ikeuchi, A.W. Russell, K.K. Ho, J.B. Prins, W.J. Inder, Longitudinal evaluation of the natural history of conservatively managed non-functioning pituitary adenomas. Clin. Endocrinol. (Oxf) (2015). doi: 10.1111\/cen.12879","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"6","key":"940_CR57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2265.2003.01784.x","volume":"58","author":"Y Greenman","year":"2003","unstructured":"Y. Greenman, G. Ouaknine, I. Veshchev, G. Reider II, Y. Segev, N. Stern, Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin. Endocrinol. (Oxf) 58(6), 763\u2013769 (2003)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"3","key":"940_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/jns\/2008\/108\/3\/0525","volume":"108","author":"M Losa","year":"2008","unstructured":"M. Losa, P. Mortini, R. Barzaghi, P. Ribotto, M.R. Terreni, S.B. Marzoli, S. Pieralli, M. Giovanelli, Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J. Neurosurg. 108(3), 525\u2013532 (2008). doi: 10.3171\/jns\/2008\/108\/3\/0525","journal-title":"J. Neurosurg."},{"issue":"4","key":"940_CR59","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3171\/jns\/2008\/108\/4\/0736","volume":"108","author":"EF Chang","year":"2008","unstructured":"E.F. Chang, G. Zada, S. Kim, K.R. Lamborn, A. Quinones-Hinojosa, J.B. Tyrrell, C.B. Wilson, S. Kunwar, Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J. Neurosurg. 108(4), 736\u2013745 (2008). doi: 10.3171\/jns\/2008\/108\/4\/0736","journal-title":"J. Neurosurg."},{"issue":"1","key":"940_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","volume":"15","author":"F Roelfsema","year":"2012","unstructured":"F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1), 71\u201383 (2012). doi: 10.1007\/s11102-011-0347-7","journal-title":"Pituitary"},{"issue":"3","key":"940_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1530\/eje-07-0502","volume":"158","author":"J Honegger","year":"2008","unstructured":"J. Honegger, S. Zimmermann, T. Psaras, M. Petrick, M. Mittelbronn, U. Ernemann, M. Reincke, K. Dietz, Growth modelling of non-functioning pituitary adenomas in patients referred for surgery. Eur. J. Endocrinol. 158(3), 287\u2013294 (2008). doi: 10.1530\/eje-07-0502","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"940_CR62","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1227\/01.neu.0000290906.53685.79","volume":"61","author":"S Yamada","year":"2007","unstructured":"S. Yamada, K. Ohyama, M. Taguchi, A. Takeshita, K. Morita, K. Takano, T. Sano, A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61(3), 580\u2013584 (2007). doi: 10.1227\/01.neu.0000290906.53685.79","journal-title":"Neurosurgery"},{"issue":"1","key":"940_CR63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12022-014-9347-2","volume":"26","author":"JA Balogun","year":"2015","unstructured":"J.A. Balogun, E. Monsalves, K. Juraschka, K. Parvez, W. Kucharczyk, O. Mete, F. Gentili, G. Zadeh, Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr. Pathol. 26(1), 63\u201370 (2015). doi: 10.1007\/s12022-014-9347-2","journal-title":"Endocr. Pathol."},{"issue":"2","key":"940_CR64","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/eje-10-0255","volume":"163","author":"S Brochier","year":"2010","unstructured":"S. Brochier, F. Galland, M. Kujas, F. Parker, S. Gaillard, C. Raftopoulos, J. Young, O. Alexopoulou, D. Maiter, P. Chanson, Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur. J. Endocrinol. 163(2), 193\u2013200 (2010). doi: 10.1530\/eje-10-0255","journal-title":"Eur. J. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0940-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-0940-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-0940-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:57:18Z","timestamp":1559440638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-0940-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,11]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-0940-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,11]]}}}